Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

2012 Methodology Report – Stakeholder Review

Stakeholder Review describing the methodology for the 2012 Access to Medicine Index and how it was developed. The report includes a set of ambitious, yet achievable expectations for company behaviour in each area measured by the Index.

Date

16 May 2012

Download this publication

The Index team, based on consultations with the industry and various civil society organisations, and in conjunction with the Expert Review Committee and Technical Subcommittees, has undertaken a review of the methodology for Index 2012. This multistakeholder consultative approach took place during 2011. It has enabled the Index team to make refinements that strive to capture the changing realities of the global health community, including the pharmaceutical industry and, most importantly, those in less affluent nations who suffer from diseases for which access to medicines is often problematic.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved